What changes the calculus: if a generic manufacturer successfully challenges Novo Nordisk's formulation patents as invalid or files an ANDA with a Paragraph IV certification (claiming the patents are invalid or not infringed), they could trigger a 30-month stay during which the FDA cannot approve the generic
Despite Wegovy and Zepbound being approved for patients with a body mass index of 30 or greater, and 27 or greater for those with at least one weight-related ailment, some insurance plans require a higher BMI or additional criteria for coverageif they cover medications for obesity at all
After doing my research, I came across glutathiosome
Interested members complete an intake questionnaire, submit a body photo, verify their identity and connect with a licensed clinician, who determines whether a microdosed GLP-1 prescription is appropriate
Again, that would typically be a good thing, suggesting that folks taking compounded versions could switch to the brand-name options, which carry the added safety of having gone through the FDA approval process (more on this below)
Research indicates combining topical 2% glutathione with oral supplementation produces superior outcomes compared to monotherapy